EVALUATION OF THE PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF INTRAVENOUS ETX2514 AND SULBACTAM ADMINISTERED CONCURRENTLY TO SUBJECTS WITH VARIOUS DEGREES OF RENAL IMPAIRMENT AND HEALTHY MATCHED CONTROL SUBJECTS: